LAVAL, Quebec, Sept. 26, 2018 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company")
announced today that it will redeem $125
million aggregate principal amount of its outstanding 7.50%
Senior Notes due 2021, CUSIP Nos. 92912EAA1, C96715AA2 (the
"Notes") on Oct. 26, 2018. Bausch
Health intends to use cash on hand to fund the aggregate redemption
price for the Notes.
Bausch Health issued today an irrevocable notice of redemption
for the Notes and a copy was issued to the record holders of such
Notes. Payment of the redemption price and surrender of the Notes
for redemption will be made through the facilities of the
Depository Trust Company in accordance with the applicable
procedures of the Depository Trust Company. The name and address of
the paying agent are as follows: The Bank of New York Mellon Trust
Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek
Parkway, East Syracuse, N.Y.
13057; Attn: Redemption Unit; Tel: 800-254-2826.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Caution Regarding Forward-Looking Information and "Safe
Harbor" Statement
This news release may contain
forward-looking statements, including, but not limited to, the
redemption of the Notes. Forward-looking statements may generally
be identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to risks and uncertainties discussed in the Company's most
recent annual and quarterly reports and detailed from time to time
in the Company's other filings with the Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-health-announces-redemption-of-125-million-aggregate-principal-amount-of-its-outstanding-7-50-senior-notes-due-2021--300719764.html
SOURCE Bausch Health Companies Inc.